Biotech Growth Trust PLC/The (BIOGl)
Market Closed
CBOE CBOE Primary LSE - Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
Want to track BIOGl and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
BIOGl is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on CBOE (GBX).
Biotech Growth Trust PLC/The (BIOGl) FAQ
On which exchange is it traded?
Biotech Growth Trust PLC/The is listed on CBOE.
What is its stock symbol?
The ticker symbol is BIOGl.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Biotech Growth Trust PLC/The ever had a stock split?
No, there has never been a stock split.
Biotech Growth Trust PLC/The Profile
| - Industry | - Sector | - CEO | CBOE Exchange | - ISIN |
| United States Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
The Biotech Growth Trust PLC is a closed-ended investment company focused on the biotechnology sector. It seeks capital appreciation by investing in a diversified portfolio of shares and related securities from biotechnology companies worldwide, spanning regions such as the United States, Netherlands, Denmark, China, United Kingdom, France, and Canada. The trust maintains a concentrated portfolio of around 77 equity holdings, with the top 10 positions—including uniQure NV, Praxis Precision Medicines Inc, Ascendis Pharma AS ADR, and UroGen Pharma Ltd—accounting for approximately 40% of assets, all allocated to the healthcare sector. Managed with an ongoing charge of 1.20% and featuring 10% gross gearing, it benchmarks against the NASDAQ Biotechnology TR GBP index. Launched in 1997 and domiciled in the United Kingdom, The Biotech Growth Trust PLC trades openly and plays a key role in providing investors access to innovative biotech firms developing therapies in areas like precision medicine and therapeutics, contributing to the growth-oriented segment of global equity markets. With total assets around £289 million, it emphasizes long-term potential in this dynamic industry.
Contact Information
Address: 601 Lexington Avenue
Phone: 212-739-6400
